A phase II, multicentre study to evaluate the long-term safety and efficacy of MT-1303 in subjects with relapsing-remitting multiple sclerosis who have completed the MT-1303-E04 study

CompletedPhase 2Relapsing MS2012-002639-27

What was tested

Treatment tested

  • Amiselimod

What it measured

Main measures

  • Safety Assessments

    Safety

Other measures (1)

  • Clinical Efficacy Endpoints:

Loading reviews and guidelines…

Related trials

History

  1. In scope changed from true to false
  1. Started

    Nov 2012

Assembled by software from public sources.